GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Conba Pharmaceutical Co Ltd (SHSE:600572) » Definitions » Debt-to-Asset

Zhejiang Conba Pharmaceutical Co (SHSE:600572) Debt-to-Asset : 0.09 (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Zhejiang Conba Pharmaceutical Co Debt-to-Asset?

Zhejiang Conba Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥651 Mil. Zhejiang Conba Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥406 Mil. Zhejiang Conba Pharmaceutical Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was ¥11,310 Mil. Zhejiang Conba Pharmaceutical Co's debt to asset for the quarter that ended in Mar. 2024 was 0.09.


Zhejiang Conba Pharmaceutical Co Debt-to-Asset Historical Data

The historical data trend for Zhejiang Conba Pharmaceutical Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Conba Pharmaceutical Co Debt-to-Asset Chart

Zhejiang Conba Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 0.26 0.13 0.11 0.09

Zhejiang Conba Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.12 0.05 0.09 0.09

Competitive Comparison of Zhejiang Conba Pharmaceutical Co's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Conba Pharmaceutical Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Conba Pharmaceutical Co's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Conba Pharmaceutical Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Zhejiang Conba Pharmaceutical Co's Debt-to-Asset falls into.



Zhejiang Conba Pharmaceutical Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Zhejiang Conba Pharmaceutical Co's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(730.339 + 305.756) / 11238.242
=0.09

Zhejiang Conba Pharmaceutical Co's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(651.406 + 406.196) / 11310.399
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhejiang Conba Pharmaceutical Co  (SHSE:600572) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Zhejiang Conba Pharmaceutical Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Zhejiang Conba Pharmaceutical Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Conba Pharmaceutical Co (SHSE:600572) Business Description

Traded in Other Exchanges
N/A
Address
No. 568 Binkang Road, New and High-Technology Development Zone, Binjiang District, Zhejiang, Hangzhou, CHN, 310052
Zhejiang Conba Pharmaceutical Co Ltd operates as a pharmaceutical company in China. It offers traditional Chinese medicines, botanical extracts, chemical medicines, chemical raw medicines, health foods, common foods, prepared drugs in pieces, and commodities. It provides its products under the Conba, Prostate Plus, Zhenshiming, Tianbaoning, Alocin, Xitao, Yuanbang, Baby, and Omeprazole names.
Executives
Hu Ji Qiang Director
Yuan Zhen Xian senior management
Yin Shi Shui Supervisors
Xu Chun Ling senior management
Jin Zu Cheng Directors, senior managers
Ye Jian Feng Supervisors
Ying Chun Xiao Director
Chen Ming Director
Luo Guo Liang Director
Wu Zhong Shi Supervisors
Wang Ru Wei Director
Yang Jun De senior management
Yang Xian Min senior management
Chen Yue Zhong senior management
Li Jian Zhong Supervisors

Zhejiang Conba Pharmaceutical Co (SHSE:600572) Headlines

No Headlines